Your shopping cart is currently empty

HSD17B13-IN-11 (Compound 2), with IC50 values of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol, effectively inhibits hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound is utilized in studying various medical conditions including liver diseases, metabolic and cardiovascular disorders, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | HSD17B13-IN-11 (Compound 2), with IC50 values of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol, effectively inhibits hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound is utilized in studying various medical conditions including liver diseases, metabolic and cardiovascular disorders, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI) [1]. |
| Molecular Weight | 352.84 |
| Formula | C16H17ClN2O3S |
| Cas No. | 2758802-03-6 |
| Smiles | C(NCC(C)C)(=O)C1=C(NC(=O)C2=CC(Cl)=C(O)C=C2)C=CS1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.